Supply of a medicinal product under the National Health Fund drug program for the treatment of patients with Pompe disease (ICD10: E74.0), containing alglucosidase alfa, for use in enzyme replacement therapy

SAMODZIELNY PUBLICZNY ZAKŁAD OPIEKI ZDROWOTNEJ W RAWIE MAZOWIECKIEJ·Rawa Mazowiecka, Poland·Deadline Jul 24, 2026 · 30 days left·Open·Supplies

Original notice title

Poland – Pharmaceutical products – Dostawa produktu leczniczego w ramach programu lekowego Narodowego Funduszu Zdrowia dotyczącego leczenia pacjentów z chorobą Pompego (ICD10: E74.0), zawierającego alglukozydazę alfa, do stosowania w enzymatycznej terapii zastępczej.

50/100

Opportunity Score

Needs reviewLow complexity

SuppliesOpen

Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

Absence of estimated value or framework maximum increases financial uncertainty for bidders.

Strict exclusion criteria including criminal records, tax arrears, and EU sanctions compliance; failure to provide corr...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Supplies contract
1 lot
Duration 24 MONTH
Supply of alglucosidase alfa (pharmaceutical product) for Pompe disease enzyme replacement therapy
Delivery to the Hospital Pharmacy Department in Rawa Mazowiecka, Poland

Show full summary

This is an open tender by a Polish public hospital for the supply of alglucosidase alfa (Pompe disease drug) under an NFZ drug program. The contract is for 24 months, with electronic submission required. The award is based solely on price (100%). No estimated value is provided. The procurement documents are available on the buyer's platform but were not analyzed.

Risks

Absence of estimated value or framework maximum increases financial uncertainty for bidders.

Strict exclusion criteria including criminal records, tax arrears, and EU sanctions compliance; failure to provide corr...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

Must hold a valid wholesale pharmaceutical permit (under Polish Pharmaceutical Law)

Eligibility

Compliance with exclusion grounds under Article 108 of the Polish Public Procurement Law and EU sanctions related to Russia

Administrative

Must submit a statement on the medicinal products (Annex 8 of SWZ)

Award Criteria

Lot 1

Price: lowest price gets highest score — 100%

Buyer

Name

SAMODZIELNY PUBLICZNY ZAKŁAD OPIEKI ZDROWOTNEJ W RAWIE MAZOWIECKIEJ

Location

Rawa Mazowiecka, POL

Website

www.szpitalrawa.pl/

Buyer profile

Open profile

Identifier

8351328753

Lots (1)

LOT-0001

Supply of a medicinal product under the National Health Fund drug program for the treatment of patients with Pompe disease (ICD10: E74.0), containing alglucosidase alfa, for use in enzyme replacement therapy

Successive delivery of alglucosidase alfa for Pompe disease enzyme replacement therapy, as detailed in Annex 2 (price form) of the procurement documents.

SuppliesEU fundedElectronic submission

Location

PL715, Poland

Duration

24 MONTH